Computational insights into inhibitory mechanism of azole compounds against human aromatase

被引:8
作者
Cai, Jinya [1 ]
Li, Junhao [1 ]
Zhang, Juan [1 ]
Ding, Shihui [1 ]
Liu, Guixia [1 ]
Li, Weihua [1 ]
Tang, Yun [1 ]
机构
[1] E China Univ Sci & Technol, Sch Pharm, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China
基金
中国国家自然科学基金;
关键词
STEERED MOLECULAR-DYNAMICS; UNBINDING PATHWAYS; ACTIVE-SITE; CYTOCHROME-P450; 3A4; CYP19; AROMATASE; FREE-ENERGIES; BINDING; RECEPTOR; PROTEIN; SIMULATIONS;
D O I
10.1039/c5ra19602g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Human aromatase, also known as cytochrome P450 19A1, specifically catalyzes the conversion of androgens to estrogens, and therefore represents an important drug target for the treatment of breast cancer. Recently, azole compounds previously used as agricultural fungicides and antimycotic drugs were reported to exhibit potent inhibitory activity against aromatase. However, the molecular mechanism of these azole compounds against aromatase remains unclear. In this study, a combination of molecular docking and several types of molecular dynamics (MD) simulations including conventional MD, random acceleration MD and steered MD, was employed to investigate the interactions of aromatase with letrozole and imazalil, two azole compounds with distinct inhibitory activities against aromatase. The binding modes of these two inhibitors were obtained by molecular docking and refined by MD simulation. The binding free energies were calculated based on the MD snapshots by using the MM-GBSA method and were found to be in agreement with the relative potency of the experimental binding affinities. Our results further demonstrated that these inhibitors had different favorable unbinding pathways in aromatase, and the unbinding manners differed in their favorable dissociation routes. Several residues lining the pathways were found important for the inhibitor egress. These findings would be helpful not only for understanding the inhibitory mechanism of azole compounds against aromatase, but also for designing new aromatase inhibitors.
引用
收藏
页码:90871 / 90880
页数:10
相关论文
共 71 条
[1]   FUNCTIONAL DOMAINS OF HUMAN AROMATASE CYTOCHROME-P450 CHARACTERIZED BY LINEAR ALIGNMENT AND SITE-DIRECTED MUTAGENESIS [J].
AMARNEH, B ;
CORBIN, CJ ;
PETERSON, JA ;
SIMPSON, ER ;
GRAHAMLORENCE, S .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (12) :1617-1624
[2]  
[Anonymous], 2012, MACROMODEL VERS 9 9
[3]  
[Anonymous], 2014, AMBER
[4]  
[Anonymous], 2012, MAESTR VERS 9 3
[5]   Aromatase: The Enzyme and Its Inhibition [J].
Banting, Lee ;
Ahmed, Sabbir .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (06) :627-641
[6]   HARMONIC-ANALYSIS OF LARGE SYSTEMS .1. METHODOLOGY [J].
BROOKS, BR ;
JANEZIC, D ;
KARPLUS, M .
JOURNAL OF COMPUTATIONAL CHEMISTRY, 1995, 16 (12) :1522-1542
[7]   Ligand unbinding from the estrogen receptor: A computational study of pathways and ligand specificity [J].
Burendahl, Sofia ;
Danciulescu, Cristian ;
Nilsson, Lennart .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2009, 77 (04) :842-856
[8]   Unbinding Pathways from the Glucocorticoid Receptor Shed Light on the Reduced Sensitivity of Glucocorticoid Ligands to a Naturally Occurring, Clinically Relevant Mutant Receptor [J].
Capelli, Anna Maria ;
Bruno, Agostino ;
Entrena Guadix, Antonio ;
Costantino, Gabriele .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (17) :7003-7014
[9]   Structure-Based Design of Potent Aromatase Inhibitors by High-Throughput Docking [J].
Caporuscio, Fabiana ;
Rastelli, Giulio ;
Imbriano, Carol ;
Del Rio, Alberto .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (12) :4006-4017
[10]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099